Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein CDV3 homolog is a ubiquitously expressed, intracellular protein encoded by the CDV3 gene, also termed carnitine deficiency-associated gene expressed in ventricle 3. The protein has a predicted molecular weight of 27.3 kDa, consists of 258 amino acids, and is found in the cytosol and potentially associated with the plasma membrane. CDV3 is proposed to act as a biomarker for hepatocellular carcinoma and has been considered as a potential target for gene therapy in cancer contexts, although there is no direct evidence it functions as a classic receptor, enzyme, or signaling target. CDV3 interacts with nuclear and cytoplasmic proteins including MYC, EWSR1, and various RNA-binding proteins, possibly implicating it in transcriptional or post-transcriptional regulation. It is also a substrate for kinase-mediated phosphorylation. Disease associations include cancer, certain genetic metabolic conditions, and possible roles in viral biology, but there are no known drugs or direct therapeutics targeting this protein currently
None established; no known pharmacological modulators
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein CDV3 homolog (CDV3).